Hyun Kang
Foot & Ankle Surgery · Garden Grove, CANPI 1184046195
Payments from drug & device makers
Across 72 payments — averaging $264.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acera Surgical, Inc.$16K
- Paratek Pharmaceuticals, Inc.$742
- Cardiovascular Systems Inc.$432
- Zimmer Biomet$423
- Amgen$308
- Smith+Nephew$152
- plus $759 from 12 others
What the payments were for
- Food & beverage$2,81615%
- Other$16,20085%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acera Surgical, Inc. | 1 | $16,200 |
| Paratek Pharmaceuticals, Inc. | 27 | $742 |
| Cardiovascular Systems Inc. | 5 | $432 |
| Zimmer Biomet | 7 | $423 |
| Amgen(2 entities) | 12 | $308 |
| Smith+Nephew | 3 | $152 |
| Linvatec Corporation | 1 | $151 |
| In2bones USA, LLC | 1 | $146 |
| AbbVie | 2 | $128 |
| Angiodynamics, Inc. | 2 | $86 |
| Kerecis Limited | 2 | $70 |
| Nevro Corp. | 2 | $57 |
| Pfizer | 2 | $30 |
| Bioventus LLC | 1 | $20 |
| Abbott | 1 | $19 |
| Organogenesis Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $18 |
| Treace Medical Concepts, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Restrata Wound Matrix$16,200
- NUZYRA$250
- BioBrace 23mm$151
- Reference Toe System$146
- CoLink$146
- Stravix$122
- Grafix$122
- GrafixPL$122
- DALVANCE$113
- Phoenix TTC Instruments and Nail$102
- Peripheral Orbital Atherectomy System$101
- AccuFill$100
How this compares
$19,016 in reported general payments places this provider in the 90th percentile of 1,126 foot & ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 1,048 | $21,413 |
| Diclofenac Sodium | 75 | $2,822 |
| Mupirocin | 343 | $1,920 |
| Econazole Nitrate | 69 | $1,343 |
| Ciclopirox | 62 | $1,120 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 80 | $865 |
| Lidocaine | 12 | $840 |
| Celecoxib | 36 | $716 |
| Clotrimazole | 21 | $629 |
| Gabapentin | 149 | $560 |
| Terbinafine Hcl | 50 | $536 |
| Fluconazole | 21 | $492 |
| Ammonium Lactate | 33 | $469 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 44 | $414 |
| Pregabalin | 16 | $214 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Garden Grove
- John ZimmermanBakersfield$4.6M
- Eric GizaSacramento$3.7M
- Thomas HarrisPasadena$3M
- Felix SigalLos Angeles$2.2M
- Thomas ChangSanta Rosa$2.1M
- Michael CoughlinSan Francisco$1.6M
- Vladimir ZeetserEncino$677K
- Jason NowakRedding$526K
- Candice BradyCamarillo$462K
- Andrew HsuOrange$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.